EUCTR2007-003060-22-DE进行中（未招募）不适用
A 24-week multicentre, randomised, double blind, controlled, parallel group non-inferiority study to assess the efficacy and safety of olmesartan medoxomil versus candesartan cilexetil in patients with symptomatic heart failure (NYHA II-IV) - OLMEBNP
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female, adult, out-patients aged between 18 and 85 years.
- •Patients with functional NYHA class ii-IV with LVEF< 40% assessed within the last 3 months,
- •Patients with blood BNP levels > 400 pg/ml or NT-ProBNP levels > 1500 pg/ml.
- •Patients with CHF due to ischemic heart disease, idiopathic dilated cardiomyopathy (IDC), mitral or aortic insufficiency or hypertension.
- •Patients with stable conventional treatment with diuretics, ACEI and/or beta-blockers and/or aldosterone antagonists for at least 2 months prior to randomisation, unless documented contraindication or intolerance.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Females who are pregnant or plan a pregnancy during the time of the trial, are nursing or are of childbearing potential and not using acceptable methods of contraception. If a female becomes pregnant during the study, she has to be withdrawn immediately.
- •Patients with current hospitalisation due to heart failure.
- •Patients with a stroke or transient ischemic attack (TIA) within the last 3 months.
- •Patients with acute coronary syndrome, myocardial infarction, coronary artery bypass or angioplasty within 3 months.
- •Planned cardiac surgery, revascularisation or resynchronisation within the study period.
- •Patients with operable valvular disease or significant obstructive cardiomyopathy.
- •Patients with bradycardia [heart rate (HR) < 50 bpm].
- •Patients with hypotension [systolic blood pressure (SBP) < 90 mmHg].
- •Patients with obstructive pneumopathy.
- •Patients with clinical significant renal failure (creatininemia > 200 micromol/l).
- •Patients with clinically significant laboratory abnormalities including:
- •- Aspartate aminotransferase (ASAT), Alanine aminotransferase (ALAT) or alkaline phosphatase (ALP) greater than 3 times the upper limit of the laboratory reference range.
- •- Bilirubine greater than twice the upper limit of the laboratory reference range.
- •- heamoglobine < 9 g/dl or < 90 g/l or 5,586 mmol/l.
- •Patients who used ARB (including olmesartan medoxomil and candesartan cilexetil) for more than 7 consecutive days within the last 3 months.
- •Patients with a betablocker therapy initiated less than 3 months before randomisation.
- •Patients with history of intolerance/ hypersensitivity to ARB, or to drugs with similar chemicals.
- •Patients with autoimmune diseases, collagenosis, insulin-dependent or poorly controlled diabetes.
研究者
相似试验
进行中（未招募）
不适用
A 24-week multicentre, randomised, double blind, controlled, parallel group non-inferiority study to assess the efficacy and safety of olmesartan medoxomil versus candesartan cilexetil in patients with symptomatic heart failure (NYHA II-IV) - OLMEBNPPatients with symptomatic, clinically stable CHF with left ventricular systolic dysfunction [NYHA class II-IV and left ventricular ejection fraction (LVEF) < 40 %] and elevated BNP levels (> 400 pg/ml or NT-ProBNP levels > 1500 pg/ml), within 90 days after discharge from a heart failure hospitalisation.MedDRA version: 9.1Level: LLTClassification code 10008908Term: <Manually entered code. Term in E.1.1>EUCTR2007-003060-22-NLDAIICHI SANKYO EUROPE GmbH400
进行中（未招募）
1 期
A 24-week multicentre, randomised, double blind, controlled, parallel group non-inferiority study to assess the efficacy and safety of olmesartan medoxomil versus candesartan cilexetil in patients with symptomatic heart failure (NYHA II-IV) - OLMEBNPEUCTR2007-003060-22-CZDAIICHI SANKYO EUROPE GmbH400
进行中（未招募）
不适用
Olpadronate intra venous in chronic low back painon-specific Chronic Low Back Pain persisting for at least 3 monthsMedDRA version: 18.1Level: LLTClassification code 10008837Term: Chronic back painSystem Organ Class: 100000004859EUCTR2015-004269-96-NLGador S.A.
已完成
2 期
A 24 weeks multicentre, randomized, double-blind, placebo-controlled, parallel group, study to evaluate the efficacy, safety and tolerability of intravenous IG-8801 20 mg and 40 mg in subjects with chronic low back paidegenerative afwijkingen van de lumbale wervelkolom leidend tot axiale aspecifieke en chronische lage rugpijnaspecific low back painchronic low back painNL-OMON46893Gador S.A.58
进行中（未招募）
不适用
ot applicable.type 2 diabetes mellitusMedDRA version: 14.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2009-017061-28-PLAstraZeneca AB940